Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022995034> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2022995034 endingPage "A103" @default.
- W2022995034 startingPage "A103.2" @default.
- W2022995034 abstract "<h3>Objectives</h3> The poor survival of cells in ischaemic myocardium is a major obstacle for stem cell therapy. Exendin-4 holds the potential of cardio protective effect based on their pleiotropicactivity. This study investigated whether Exendin-4 in conjunction with adipose derived stem cells (ADSCs) could improve the stem cells survival and contribute to myocardial repair after myocardial infarction. <h3>Methods</h3> MI was induced by the left anterior descending artery ligation in adult male Sprague-Dawley rats. ADSCs carrying double-fusion reporter gene (fire flyluciferase and monomeric red fluorescent protein (fluc-mRFP)) were quickly injected into border zone of myocardial infarction in rats treated with or without Exendin-4. <h3>Results</h3> Longitudinal <i>in vivo</i> bioluminescence imaging indicated that Exendin-4 enhanced the survival of transplanted ADSCs. Moreover, ADSCs adjuvant with Exendin-4 decreased oxidativestress, apoptosis and fibrosis, improved myocardial viability and cardiac function, as well as increased the differentiation rates of ADSCs into cardiomyocyte sand vascular smooth muscle cells <i>in vivo</i>. Then, ADSCs were exposed to hydrogen peroxide/serum deprivation (H<sub>2</sub>O<sub>2/</sub>SD) to mimic the ischaemic environment <i>in vitro</i>. Exendin-4 decreased the apoptosis and enhanced the paracrine effect of ADSCs. Western blotting demonstrated that Exendin-4 activated STAT3 through the phosphorylation of Akt and ERK1/2. Furthermore, Exendin-4 increased theanti-apoptotic protein Bcl-2 and decreased the pro-apoptotic protein Bax of ADSCs. <h3>Conclusions</h3> Exendin-4 could improve the survival and therapeutic efficacy of transplanted ADSCs through STAT3 activation via the phosphorylation of Akt and ERK1/2. This study suggests the potential of Exendin-4 for stem cell based heart regeneration." @default.
- W2022995034 created "2016-06-24" @default.
- W2022995034 creator A5080241619 @default.
- W2022995034 creator A5084136821 @default.
- W2022995034 date "2013-08-01" @default.
- W2022995034 modified "2023-10-16" @default.
- W2022995034 title "GW24-e3600 The Stem Cell Adjuvant with Exendin-4 Enhances the Therapeutic Efficacy for Myocardial Infarction via STAT3 Activation" @default.
- W2022995034 doi "https://doi.org/10.1136/heartjnl-2013-304613.280" @default.
- W2022995034 hasPublicationYear "2013" @default.
- W2022995034 type Work @default.
- W2022995034 sameAs 2022995034 @default.
- W2022995034 citedByCount "0" @default.
- W2022995034 crossrefType "journal-article" @default.
- W2022995034 hasAuthorship W2022995034A5080241619 @default.
- W2022995034 hasAuthorship W2022995034A5084136821 @default.
- W2022995034 hasConcept C126322002 @default.
- W2022995034 hasConcept C150903083 @default.
- W2022995034 hasConcept C170493617 @default.
- W2022995034 hasConcept C179437574 @default.
- W2022995034 hasConcept C185592680 @default.
- W2022995034 hasConcept C190283241 @default.
- W2022995034 hasConcept C207001950 @default.
- W2022995034 hasConcept C28328180 @default.
- W2022995034 hasConcept C2911091166 @default.
- W2022995034 hasConcept C500558357 @default.
- W2022995034 hasConcept C502942594 @default.
- W2022995034 hasConcept C55493867 @default.
- W2022995034 hasConcept C71924100 @default.
- W2022995034 hasConcept C7876069 @default.
- W2022995034 hasConcept C86803240 @default.
- W2022995034 hasConcept C95444343 @default.
- W2022995034 hasConceptScore W2022995034C126322002 @default.
- W2022995034 hasConceptScore W2022995034C150903083 @default.
- W2022995034 hasConceptScore W2022995034C170493617 @default.
- W2022995034 hasConceptScore W2022995034C179437574 @default.
- W2022995034 hasConceptScore W2022995034C185592680 @default.
- W2022995034 hasConceptScore W2022995034C190283241 @default.
- W2022995034 hasConceptScore W2022995034C207001950 @default.
- W2022995034 hasConceptScore W2022995034C28328180 @default.
- W2022995034 hasConceptScore W2022995034C2911091166 @default.
- W2022995034 hasConceptScore W2022995034C500558357 @default.
- W2022995034 hasConceptScore W2022995034C502942594 @default.
- W2022995034 hasConceptScore W2022995034C55493867 @default.
- W2022995034 hasConceptScore W2022995034C71924100 @default.
- W2022995034 hasConceptScore W2022995034C7876069 @default.
- W2022995034 hasConceptScore W2022995034C86803240 @default.
- W2022995034 hasConceptScore W2022995034C95444343 @default.
- W2022995034 hasIssue "Suppl 3" @default.
- W2022995034 hasLocation W20229950341 @default.
- W2022995034 hasOpenAccess W2022995034 @default.
- W2022995034 hasPrimaryLocation W20229950341 @default.
- W2022995034 hasRelatedWork W2120735623 @default.
- W2022995034 hasRelatedWork W2279654533 @default.
- W2022995034 hasRelatedWork W2316107365 @default.
- W2022995034 hasRelatedWork W2332114915 @default.
- W2022995034 hasRelatedWork W2365844738 @default.
- W2022995034 hasRelatedWork W2367140913 @default.
- W2022995034 hasRelatedWork W2377483921 @default.
- W2022995034 hasRelatedWork W2437485626 @default.
- W2022995034 hasRelatedWork W2894060815 @default.
- W2022995034 hasRelatedWork W4232554619 @default.
- W2022995034 hasVolume "99" @default.
- W2022995034 isParatext "false" @default.
- W2022995034 isRetracted "false" @default.
- W2022995034 magId "2022995034" @default.
- W2022995034 workType "article" @default.